Neurovance Garners $4,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d8a97f4b-bcd9-413c-966b-a09ff86407ae - Date
9/2/2014 - Company Name
Neurovance - Mailing Address
43 Thorndike Street Cambridge, MA 02141 USA - Company Description
Neurovance is a clinical stage neuroscience-focused company. Following development of centanafadine SR (formerly EB-1020 SR) for adult ADHD, Neurovance will develop centanafadine SR for adolescent and pediatric ADHD. - Website
http://www.neurovance.com - Transaction Type
Venture Equity - Transaction Amount
$4,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities. - M&A Terms
- Venture Investor
